EA could improve gastric motility dysfunction and attenuate ICC apoptosis possibly through the regulation of IGF-1/IGF-1R and Nrf2/HO-1 pathways. The gene discussed is NFE2L2; the disease is intrahepatic cholangiocarcinoma.